Bailong Chuangyuan(SH:605016) Xin Lang Cai Jing·2025-10-31 07:56Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, benefiting from its unique product offerings and market positioning in the sugar substitute sector. Group 1: Company Performance - For the period from January to September 2025, the company achieved operating revenue of 969 million yuan, representing a year-on-year growth of 18.10% [8] - The net profit attributable to the parent company was 265 million yuan, reflecting a year-on-year increase of 44.93% [8] - The company has a market capitalization of 8.497 billion yuan, with a trading volume of 167 million yuan and a turnover rate of 1.96% on October 31 [1] Group 2: Product and Market Positioning - The company specializes in health sweeteners, particularly allulose, which is a rare monosaccharide that closely resembles sucrose in taste but has significantly lower calories, making it ideal for obesity and diabetes patients [2] - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [4] Group 3: Shareholding and Institutional Investment - As of September 30, 2025, the company held a 5.14% stake in Shandong Yucheng Rural Commercial Bank [3] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Penghua New Emerging Industries Mixed A, with some fluctuations in their holdings [10] Group 4: Revenue Composition - The company's main business revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]